Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas

Alberto Mussetti, Nicolò Martinetti, Nicoletta Cieri, Martina Pennisi, Anna Dodero, Paolo Corradini

Research output: Contribution to journalArticle

Abstract

Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.

Original languageEnglish
Pages (from-to)1237-1244
Number of pages8
JournalBone Marrow Transplantation
Volume54
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Peripheral T-Cell Lymphoma
Homologous Transplantation
Survival
Transplants
T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Disease Progression
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. / Mussetti, Alberto; Martinetti, Nicolò; Cieri, Nicoletta; Pennisi, Martina; Dodero, Anna; Corradini, Paolo.

In: Bone Marrow Transplantation, Vol. 54, No. 8, 01.08.2019, p. 1237-1244.

Research output: Contribution to journalArticle

Mussetti, Alberto ; Martinetti, Nicolò ; Cieri, Nicoletta ; Pennisi, Martina ; Dodero, Anna ; Corradini, Paolo. / Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. In: Bone Marrow Transplantation. 2019 ; Vol. 54, No. 8. pp. 1237-1244.
@article{be54e660143448ca8ca4e11eb4204585,
title = "Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas",
abstract = "Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14{\%} (CI95{\%}:7–24) and 34{\%} (CI95{\%}:22–46). Extranodal disease at relapse (HR 2.25, CI95{\%}: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95{\%}: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62{\%}) received allogeneic transplant. For the 28 (38{\%}) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45{\%} vs 73{\%}, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.",
author = "Alberto Mussetti and Nicol{\`o} Martinetti and Nicoletta Cieri and Martina Pennisi and Anna Dodero and Paolo Corradini",
year = "2019",
month = "8",
day = "1",
doi = "10.1038/s41409-018-0417-9",
language = "English",
volume = "54",
pages = "1237--1244",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas

AU - Mussetti, Alberto

AU - Martinetti, Nicolò

AU - Cieri, Nicoletta

AU - Pennisi, Martina

AU - Dodero, Anna

AU - Corradini, Paolo

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.

AB - Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.

UR - http://www.scopus.com/inward/record.url?scp=85058190702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058190702&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0417-9

DO - 10.1038/s41409-018-0417-9

M3 - Article

C2 - 30531956

AN - SCOPUS:85058190702

VL - 54

SP - 1237

EP - 1244

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -